July 25, 2006 -- Momenta Pharma signed a $263 million deal with Sandoz, the generic division of Novartis, to develop generic biotech drugs; Encysive received a second approvable letter for Thelin; Enzon received FDA approval for first-line use of Oncaspar as a leukemia therapy; Asthmatx, an asthma drug company, will seek to raise up to $75 million in an IPO; Althus Pharma delayed plans for Phase III trials for two of its drugs; and Oscient acquired US rights to Antara, a cholesterol drug from Reliant. The Centient Biotech 200™ moved up 57 points to 3645.94, a rise of 1.58%. More details...
